Figure 2 | Modern Pathology

Figure 2

From: Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients

Figure 2

(a) Minimum serum prostate-specific antigen (PSA) level after androgen-deprivation therapy (ADT) for strongly positive AR-V7 (Immune-Reactive Score ≥9, black plot), moderately positive AR-V7 (9>Immune-Reactive Score≥2, gray plot) and AR-V7-negative (Immune-Reactive Score <2, light gray plot). Black crosshairs denote the median PSA with 95% CI. (b) The time to castration-resistant prostate cancer (CRPC) progression after androgen-deprivation therapy in the AR-V7-positive and AR-V7-negative groups. Black crosshairs denote the median time to CPRC progression with 95% CI. P-values are for Student’s t-tests.

Back to article page